Tharimmune, Inc. (NASDAQ:THAR - Get Free Report) COO Sireesh Appajosyula purchased 5,000 shares of Tharimmune stock in a transaction dated Wednesday, November 13th. The stock was acquired at an average price of $2.02 per share, with a total value of $10,100.00. Following the acquisition, the chief operating officer now owns 10,758 shares in the company, valued at approximately $21,731.16. This represents a 0.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Sireesh Appajosyula also recently made the following trade(s):
- On Tuesday, October 8th, Sireesh Appajosyula bought 5,000 shares of Tharimmune stock. The shares were acquired at an average price of $1.93 per share, for a total transaction of $9,650.00.
Tharimmune Trading Down 0.9 %
THAR stock opened at $2.13 on Thursday. Tharimmune, Inc. has a 52 week low of $1.84 and a 52 week high of $81.53. The firm has a 50 day moving average of $2.47 and a 200 day moving average of $3.39.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC purchased a new stake in Tharimmune, Inc. (NASDAQ:THAR - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 23,620 shares of the company's stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent SEC filing. Institutional investors own 1.16% of the company's stock.
Tharimmune Company Profile
(
Get Free Report)
Central Bank Abandons USD
From True Gold Republic | Ad
Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar…
And placing a ‘quiet bet’ on a new type of currency…
Gold.
Click here now to get your free 'Protect Your Wealth' Guide.
Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
